Skip to content

OP Device vs. Bone Autograft for the Treatment of Tibial Nonunions

Study #91-01 - A Randomized Study of the Stryker OP Device vs. Bone Autograft for the Treatment of Tibial Nonunions

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00679328
Enrollment
122
Registered
2008-05-16
Start date
1992-02-29
Completion date
1999-12-31
Last updated
2011-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tibial Nonunions

Brief summary

This study is to evaluate the safety and effectiveness of the OP device for the treatment of nonunion bone fractures and to compare the healing rates of the OP Device to that of autograft.

Detailed description

This study is to evaluate the safety and effectiveness of the OP device for the treatment of nonunion bone fractures and to compare the clinical safety and effectiveness (healing rates) of the OP Device to that of traditional bone autografts to repair nonunions.

Interventions

DEVICESurgical implantation of OP-1 device or autograft bone graft material

Surgical implantation of OP-1 device or autograft bone graft material

Sponsors

Olympus Biotech Corporation
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Patients must show radiographic skeletal maturity 2. Documented evidence of previous fracture management 3. Nonunion in the tibia and candidate to receive bone autografts and intramedullary (IM) Nail fixation 4. Nonunion gap must not exceed half the diameter of the bone at the site of fracture, as assessed radiographically prior to study treatment

Exclusion criteria

1. Patients who do not have adequate vascularity to permit healing 2. Patients with inadequate skin coverage 3. Patients with chronic use of steroidal medications 4. Patients with active infection systemically or at the site of nonunion.

Design outcomes

Primary

MeasureTime frame
No further retreatment of the surgical site, function and pain at the site of the nonunion, evidence of bridging.3, 6, 9, 12, 24 months

Secondary

MeasureTime frame
Medical events, treatment related events, laboratory tests, medication use.3, 6, 9, 12, 24 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026